IL-22BP controls the progression of liver metastasis in colorectal cancer

Anastasios D. Giannou; Jan Kempski; Tao Zhang; Jöran Lücke; Ahmad Mustafa Shiri; Dimitra E. Zazara; Ioannis Belios; Andres Machicote; Philipp Seeger; Theodora Agalioti; Joseph Tintelnot; Adrian Sagebiel; Miriam Tomczak; Lennart Bauditz; Tanja Bedke; Lorenz Kocheise; Baris Mercanoglu; Mohammad Fard-Aghaie; Emmanouil Giorgakis; Panagis M. Lykoudis; Anastasia Pikouli; Julia Kristin Grass; Ramez Wahib; Jan Bardenhagen; Benjamin Brunswig; Asmus Heumann; Tarik Ghadban; Anna Duprée; Michael Tachezy; Nathaniel Melling; Petra C. Arck; Pablo Stringa; Maria Virginia Gentilini; Gabriel E. Gondolesi; Ryosuke Nakano; Angus W. Thomson; Daniel Perez; Jun Li; Oliver Mann; Jakob R. Izbicki; Nicola Gagliani; Ioannis C. Maroulis; Samuel Huber

doi:10.3389/fonc.2023.1170502

IL-22BP controls the progression of liver metastasis in colorectal cancer

Anastasios D. Giannou, Jan Kempski, Tao Zhang, Jöran Lücke, Ahmad Mustafa Shiri, Dimitra E. Zazara, Ioannis Belios, Andres Machicote, Philipp Seeger, Theodora Agalioti, Joseph Tintelnot, Adrian Sagebiel, Miriam Tomczak, Lennart Bauditz, Tanja Bedke, Lorenz Kocheise, Baris Mercanoglu, Mohammad Fard-Aghaie, Emmanouil Giorgakis, Panagis M. LykoudisAnastasia Pikouli, Julia Kristin Grass, Ramez Wahib, Jan Bardenhagen, Benjamin Brunswig, Asmus Heumann, Tarik Ghadban, Anna Duprée, Michael Tachezy, Nathaniel Melling, Petra C. Arck, Pablo Stringa, Maria Virginia Gentilini, Gabriel E. Gondolesi, Ryosuke Nakano, Angus W. Thomson, Daniel Perez, Jun Li, Oliver Mann, Jakob R. Izbicki, Nicola Gagliani, Ioannis C. Maroulis, Samuel Huber

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown. Methods: We used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages. Results: Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice. Conclusions: We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.

Original language	English
Article number	1170502
Journal	Frontiers in Oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.1170502
State	Published - 2023
Externally published	Yes

Keywords

IL-22BP
cancer therapy
colorectal cancer
metastasis
tumor immunology

Access to Document

10.3389/fonc.2023.1170502

Cite this

Giannou, A. D., Kempski, J., Zhang, T., Lücke, J., Shiri, A. M., Zazara, D. E., Belios, I., Machicote, A., Seeger, P., Agalioti, T., Tintelnot, J., Sagebiel, A., Tomczak, M., Bauditz, L., Bedke, T., Kocheise, L., Mercanoglu, B., Fard-Aghaie, M., Giorgakis, E., ... Huber, S. (2023). IL-22BP controls the progression of liver metastasis in colorectal cancer. Frontiers in Oncology, 13, Article 1170502. https://doi.org/10.3389/fonc.2023.1170502

@article{a17a8cfc006c4ade947728d7c10638c4,

title = "IL-22BP controls the progression of liver metastasis in colorectal cancer",

abstract = "Background: The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown. Methods: We used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages. Results: Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice. Conclusions: We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.",

keywords = "IL-22BP, cancer therapy, colorectal cancer, metastasis, tumor immunology",

author = "Giannou, {Anastasios D.} and Jan Kempski and Tao Zhang and J{\"o}ran L{\"u}cke and Shiri, {Ahmad Mustafa} and Zazara, {Dimitra E.} and Ioannis Belios and Andres Machicote and Philipp Seeger and Theodora Agalioti and Joseph Tintelnot and Adrian Sagebiel and Miriam Tomczak and Lennart Bauditz and Tanja Bedke and Lorenz Kocheise and Baris Mercanoglu and Mohammad Fard-Aghaie and Emmanouil Giorgakis and Lykoudis, {Panagis M.} and Anastasia Pikouli and Grass, {Julia Kristin} and Ramez Wahib and Jan Bardenhagen and Benjamin Brunswig and Asmus Heumann and Tarik Ghadban and Anna Dupr{\'e}e and Michael Tachezy and Nathaniel Melling and Arck, {Petra C.} and Pablo Stringa and Gentilini, {Maria Virginia} and Gondolesi, {Gabriel E.} and Ryosuke Nakano and Thomson, {Angus W.} and Daniel Perez and Jun Li and Oliver Mann and Izbicki, {Jakob R.} and Nicola Gagliani and Maroulis, {Ioannis C.} and Samuel Huber",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Giannou, Kempski, Zhang, L{\"u}cke, Shiri, Zazara, Belios, Machicote, Seeger, Agalioti, Tintelnot, Sagebiel, Tomczak, Bauditz, Bedke, Kocheise, Mercanoglu, Fard-Aghaie, Giorgakis, Lykoudis, Pikouli, Grass, Wahib, Bardenhagen, Brunswig, Heumann, Ghadban, Dupr{\'e}e, Tachezy, Melling, Arck, Stringa, Gentilini, Gondolesi, Nakano, Thomson, Perez, Li, Mann, Izbicki, Gagliani, Maroulis and Huber.",

year = "2023",

doi = "10.3389/fonc.2023.1170502",

language = "English",

volume = "13",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

Giannou, AD, Kempski, J, Zhang, T, Lücke, J, Shiri, AM, Zazara, DE, Belios, I, Machicote, A, Seeger, P, Agalioti, T, Tintelnot, J, Sagebiel, A, Tomczak, M, Bauditz, L, Bedke, T, Kocheise, L, Mercanoglu, B, Fard-Aghaie, M, Giorgakis, E, Lykoudis, PM, Pikouli, A, Grass, JK, Wahib, R, Bardenhagen, J, Brunswig, B, Heumann, A, Ghadban, T, Duprée, A, Tachezy, M, Melling, N, Arck, PC, Stringa, P, Gentilini, MV, Gondolesi, GE, Nakano, R, Thomson, AW, Perez, D, Li, J, Mann, O, Izbicki, JR, Gagliani, N, Maroulis, IC & Huber, S 2023, 'IL-22BP controls the progression of liver metastasis in colorectal cancer', Frontiers in Oncology, vol. 13, 1170502. https://doi.org/10.3389/fonc.2023.1170502

TY - JOUR

T1 - IL-22BP controls the progression of liver metastasis in colorectal cancer

AU - Giannou, Anastasios D.

AU - Kempski, Jan

AU - Zhang, Tao

AU - Lücke, Jöran

AU - Shiri, Ahmad Mustafa

AU - Zazara, Dimitra E.

AU - Belios, Ioannis

AU - Machicote, Andres

AU - Seeger, Philipp

AU - Agalioti, Theodora

AU - Tintelnot, Joseph

AU - Sagebiel, Adrian

AU - Tomczak, Miriam

AU - Bauditz, Lennart

AU - Bedke, Tanja

AU - Kocheise, Lorenz

AU - Mercanoglu, Baris

AU - Fard-Aghaie, Mohammad

AU - Giorgakis, Emmanouil

AU - Lykoudis, Panagis M.

AU - Pikouli, Anastasia

AU - Grass, Julia Kristin

AU - Wahib, Ramez

AU - Bardenhagen, Jan

AU - Brunswig, Benjamin

AU - Heumann, Asmus

AU - Ghadban, Tarik

AU - Duprée, Anna

AU - Tachezy, Michael

AU - Melling, Nathaniel

AU - Arck, Petra C.

AU - Stringa, Pablo

AU - Gentilini, Maria Virginia

AU - Gondolesi, Gabriel E.

AU - Nakano, Ryosuke

AU - Thomson, Angus W.

AU - Perez, Daniel

AU - Li, Jun

AU - Mann, Oliver

AU - Izbicki, Jakob R.

AU - Gagliani, Nicola

AU - Maroulis, Ioannis C.

AU - Huber, Samuel

N1 - Publisher Copyright: Copyright © 2023 Giannou, Kempski, Zhang, Lücke, Shiri, Zazara, Belios, Machicote, Seeger, Agalioti, Tintelnot, Sagebiel, Tomczak, Bauditz, Bedke, Kocheise, Mercanoglu, Fard-Aghaie, Giorgakis, Lykoudis, Pikouli, Grass, Wahib, Bardenhagen, Brunswig, Heumann, Ghadban, Duprée, Tachezy, Melling, Arck, Stringa, Gentilini, Gondolesi, Nakano, Thomson, Perez, Li, Mann, Izbicki, Gagliani, Maroulis and Huber.

PY - 2023

Y1 - 2023

N2 - Background: The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown. Methods: We used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages. Results: Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice. Conclusions: We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.

AB - Background: The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown. Methods: We used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages. Results: Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice. Conclusions: We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.

KW - IL-22BP

KW - cancer therapy

KW - colorectal cancer

KW - metastasis

KW - tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=85162006439&partnerID=8YFLogxK

U2 - 10.3389/fonc.2023.1170502

DO - 10.3389/fonc.2023.1170502

M3 - Article

AN - SCOPUS:85162006439

SN - 2234-943X

VL - 13

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1170502

ER -

IL-22BP controls the progression of liver metastasis in colorectal cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this